Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 53 articles:
HTML format
Text format



Single Articles


    September 2017
  1. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available


  2. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    PubMed     Text format     Abstract available


    August 2017
  3. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2017;28:1700-1712.
    PubMed     Text format     Abstract available


  4. DEL MASTRO L, Lambertini M
    Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?
    Ann Oncol. 2017;28:1683-1685.
    PubMed     Text format    


  5. GERMA C, Miller M, Mukhopadhyay P, Hewes B, et al
    Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.
    Ann Oncol. 2017;28:2021-2024.
    PubMed     Text format    


    July 2017

  6. Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
    Ann Oncol. 2017;28.
    PubMed     Text format    


    June 2017
  7. OHGAMI M, Bando H, Ishiguro H, Tsuda M, et al
    Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
    Ann Oncol. 2017 Jun 26. doi: 10.1093.
    PubMed     Text format    


  8. BLACKWELL K, Gascon P, Jones CM, Nixon A, et al
    Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Ann Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  9. ALI HR, Dariush A, Thomas J, Provenzano E, et al
    Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
    Ann Oncol. 2017 May 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. SPERA G, Fresco R, Fung H, Dyck JRB, et al
    Beta Blockers and Improved Progression Free Survival in Patients with Advanced HER2 Negative Breast Cancer: a Retrospective Analysis of the ROSE/TRIO-012 Study.
    Ann Oncol. 2017 May 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. SASADA S, Kurihara H, Kinoshita T, Yoshida M, et al
    64Cu-DOTA-Trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  12. MAMIYA H, Tahara RK, Tolaney SM, Choudhry N, et al
    Cost-Effectiveness of Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer.
    Ann Oncol. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. LEONARD R, Adamson D, Bertelli G, Mansi J, et al
    GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
    Ann Oncol. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. LESURF R, Griffith OL, Griffith M, Hundal J, et al
    Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
    Ann Oncol. 2017;28:1070-1077.
    PubMed     Text format     Abstract available


    April 2017
  15. KUIJER A, Verloop J, Visser O, Sonke G, et al
    The influence of socio-economic status and ethnicity on adjuvant systemic treatment guideline adherence for early stage breast cancer in the Netherlands.
    Ann Oncol. 2017 Apr 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. MOEBUS V, von Minckwitz G, Jackisch C, Luck HJ, et al
    German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. EARL HM, Hiller L, Dunn J, Blenkinsop C, et al
    Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
    Ann Oncol. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. WEIN L, Savas P, Van Geelan C, Caramia F, et al
    FGFR2 amplification in metastatic hormone positive breast cancer and response to an mTOR inhibitor.
    Ann Oncol. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format    


    March 2017
  19. YERUSHALMI R, Dong B, Chapman JW, Goss PE, et al
    Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
    Ann Oncol. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. TREDAN O, Menetrier-Caux C, Ray-Coquard I, Garin G, et al
    ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format    


  21. CURIGLIANO G, Goldhirsch A
    Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.
    Ann Oncol. 2017;28:441-443.
    PubMed     Text format    


    February 2017
  22. LESURF R, Griffith OL, Griffith M, Hundal J, et al
    Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2017 Feb 19. doi: 10.1093.
    PubMed     Text format    


  24. CURIGLIANO G, Goldhirsch A
    Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    January 2017
  25. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2017 Jan 5. pii: mdw695. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. PIERGA JY, Bidard FC, Autret A, Petit T, et al
    Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Ann Oncol. 2017;28:103-109.
    PubMed     Text format    


  27. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Common breast cancer risk alleles and risk assessment: a study on 35 441 individuals from the Danish general population.
    Ann Oncol. 2017;28:175-181.
    PubMed     Text format    


  28. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2017;28:16-33.
    PubMed     Text format    


  29. COSTA R, Carneiro BA, Wainwright DA, Santa-Maria CA, et al
    Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
    Ann Oncol. 2017;28:44-56.
    PubMed     Text format    


    December 2016
  30. M-RABET M, Cabaud O, Josselin E, Finetti P, et al
    Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    Ann Oncol. 2016 Dec 20. pii: mdw678. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. KHOSROW-KHAVAR F, Filion KB, Al-Qurashi S, Torabi N, et al
    Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ann Oncol. 2016 Dec 20. pii: mdw673. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. PAGANI O, Klingbiel D, Ruhstaller T, Nole F, et al
    Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99.
    Ann Oncol. 2016 Dec 19. pii: mdw622. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. BELL R, Brown J, Parmar M, Toi M, et al
    Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  34. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2016.
    PubMed     Text format    


    November 2016
  36. CARDOSO F, Harbeck N, Barrios CH, Bergh J, et al
    Research needs in breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  37. LOIBL S, Jackisch C, Schneeweiss A, Schmatloch S, et al
    Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  38. MARTIN M, Chan A, Dirix L, O'Shaughnessy J, et al
    A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  39. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Common breast cancer risk alleles and risk assessment: A study on 35,441 individuals from the Danish general population.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  40. COSTA R, Carneiro BA, Wainwright DA, Santa-Maria CA, et al
    Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  41. NITZ U, Gluz O, Huober J, Kreipe HH, et al
    Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
    Ann Oncol. 2016.
    PubMed     Text format    


    August 2016
  42. WOODS LM, Morris M, Rachet B
    No 'cure' within 12 years of diagnosis amongst breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989-2011.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  43. VUYLSTEKE P, Huizing M, Petrakova K, Roylance R, et al
    Pictilisib plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  44. MAVROUDIS D, Matikas A, Malamos N, Papakotoulas P, et al
    Dose-dense FEC followed by Docetaxel versus Docetaxel plus Cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  45. VRDOLJAK E, Marschner N, Zielinski C, Gligorov J, et al
    Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  46. DIECI MV, Prat A, Tagliafico E, Pare L, et al
    Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  47. DELALOGE S, Perol D, Courtinard C, Brain E, et al
    Paclitaxel plus Bevacizumab or Paclitaxel as First-line Treatment for HER2-Negative Metastatic Breast Cancer in a Multicenter National Observational Study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  48. JERUSALEM G, Mariani G, Ciruelos EM, Martin M, et al
    Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm,
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  49. GOEL S, Krop IE
    PIK3CA mutations in HER2-positive breast cancer - an ongoing conundrum.
    Ann Oncol. 2016.
    PubMed     Text format    


    May 2016
  50. WINTER C, Nilsson MP, Olsson E, George AM, et al
    Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests one third of mutations are somatic.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  51. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer - pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  52. PIVOT X, Marme F, Koenigsberg R, Guo M, et al
    Pooled analyses of eribulin in metastatic breast cancer patients with at least 1 prior chemotherapy.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  53. RODRIGUEZ-WALLBERG K, Turan V, Munster P, Oktay K, et al
    Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
    Ann Oncol. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: